Erythropoietic Protoporphyria (EPP) is an inherited disorder of porphyrin metabolism in which decreased activity of ferrochelatase (FECH) leads to accumulation of protoporphyrin IX (PP IX) in red blood cells, plasma, liver, bile and increased excretion in feces. Clinically, EPP is characterized by photosensitivity that includes burning, swelling, itching and painful erythema in sun exposed areas from early childhood. Chronic liver disease is an important complication in a minority of EPP patients and in some cases liver transplantation has been performed. So far, about 110 different mutations and several polymorphisms have been characterized in the human FECH gene. The relationship between mutations, polymorphisms and porphyria development in Argentinean patients was investigated. This is the first genetic study carried out in the Argentinean population. In five Argentinean EPP families we detected 3 novel mutations: a deletion (451delT) producing a stop codon 18 codons downstream from the mutation and 2 splicing mutations: IVS1-2A>G leading to exon 2 skipping and IVS4-2A>G which causes the loss of the first 48bp of exon 5. We have also found 2 previously described mutations: C343T and 400delA producing stop codons. All patients had a FECH activity 25% of normal and also had the polymorphisms -251A>G in the promoter region, IVS1-23 C>T and IVS3-48 T>C.
INTRODUCTION
Erythropoietic Protoporphyria (EPP, MIM 17.700) is an inherited disorder of porphyrin metabolism first described by Magnus et al (1) . EPP is due to a decreased activity of ferrochelatase (FECH) (E.C. 4 .99.1.1), the enzyme which catalyses the chelation of iron into PP IX to form heme. The deficient activity leads to the accumulation of PP IX in red blood cells, plasma, liver and bile and an increased excretion in the feces (Fig1).
Clinically, EPP is characterized by photosensitivity that includes burning, swelling, itching and painful erythema in sun exposed areas from early childhood. Chronic liver disease is an important complication in a minority of EPP patients (2, 3) , while it can reach up to 30% in other EPP patients (4) . In a limited number of cases, liver transplantation has been performed (2,3).
The human FECH gene was cloned, sequenced and mapped to the long arm of chromosome 18 (5, 6) . The gene contains a total of 11 exons and spans about 45kb of genomic DNA. The cDNA has an open reading frame of 1269 bp encoding a protein of 423 amino acid residues. The mature protein consists of 369 amino acids (7) .
So far, more than 110 different mutations have been characterized in the human FECH gene, of which about 70% are null allele mutations (Human Gene Mutation Database: http://www.hgmd.org/. In addition, several polymorphisms have also been detected (http://www.ncbi.nlm.nih.gov/SNP).
In most cases, only one gene allele is affected by an inactivating mutation. EPP is transmitted as an autosomal dominant trait but with a low clinical penetrance because most mutation carriers remain asymptomatic despite having a FECH activity of about 50% of normal. In symptomatic individuals with EPP the activity of FECH is in general lower than the 50% that would be expected from an autosomal dominant inherited disease. Brenner's hypothesis (8) that the mutated FECH allele could have a dominant negative effect would explain the reduced enzyme activity observed in patients but it does not explain the incomplete penetrance found in EPP families. In 1996 Gouya et al (9) showed that the EPP phenotype in an affected family was the result of the coinheritance of a normal allele of low Molecular Medicine www.molmed.org UNCORRECTED PROOF expression (about 50%) and a mutant allele. Later, it was proposed that this low expression allele which co-inherits with a mutated allele resulting in an overt EPP, being strongly associated with the haplotype -251G: IVS1-23T: IVS2μsatA9, which was present in about 6.5 -11.5% of a control group (10) . More recently, it was established that the mechanism responsible for the low expression FECH was the IVS3-48T>C transition that modulates the use of a constitutive aberrant splice site, 63 bp upstream of the normal site. Thus, the presence of a T in the position IVS3-48 was shown to produce about 20% aberrantly spliced mRNA while the presence of a C in this position lead to a higher presence, about 40%, of the abnormal mRNA which would be easily degraded by the so-called nonsense mediated mRNA decay, producing a lower steady-state level of FECH mRNA (11, 12) . Although the inheritance of an IVS3-48C allele trans to the mutation explained the phenotypic expression in most families (4, (12) (13) (14) , autosomal recessive inheritance can cause overt EPP in patients who do not have the low expression allele. A small number of cases of recessive inheritance have been reported (15, 16) .
To date, 41 individuals from 35 families have been diagnosed as having EPP in our Research
Centre on Porphyrins and Porphyrias in Argentina. This is the first study of Argentinean unrelated EPP families at the molecular level. We looked for the mutation in the FECH gene as well as three of the reported polymorphisms associated with the low-expression allele. Three novel null mutations, two splicing defects and one small deletion, and two previously reported mutations were found. All patients were heterozygous carriers of EPP and all symptomatic individuals in each family also inherited the IVS3-48C allele strongly associated with the low-expression FECH allele. These results in Argentinean EPP patients provide support for the proposed mechanism for the phenotypic expression of EPP and reinforce the idea that this is a general phenomenon for this Porphyria.
MATERIALS AND METHODS

Biochemical studies
Peripheral blood samples were collected in heparinized test tubes from the patients and their relatives.
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Total porphyrins in whole blood samples and feces and plasma porphyrins (PPI index) were measured by methods previously described (17) . Ferrochelatase was measured with a modified method which was a combination of those described by Li & Lim (18) and Rossi et al (19) and erythrocyte protoporphyrin was quantified by the modified method of Bailey & Needman (20) . Biochemical data are shown in Table 1 .
Mutational Analysis
Genomic DNA was isolated from peripheral EDTA blood samples using the InstaGene Whole Blood Kit (Bio Rad) according to the manufacturers instructions.
Total RNA was isolated from Epstein-Barr virus transfected lymphoblastoid cell lines (Neitzel, 1986 ) (21) and complementary DNA was obtained with Reverse Transcriptase.
The 11 exons of FECH, including the flanking intronic regions, were amplified by the polymerase chain reaction with the primers listed in Table 2 (according to the published FECH sequence No AJ250235). Sequencing was performed using a DNA sequencing kit (Applied Biosystems), and reactions were run on an ABI PRISM 310 Genetic Analyzer (Perkin Elmer). Amplification of cDNA samples were performed with primers listed in Table 2 , and PCR products were sequenced with internal primers Polymorphisms -251 A>G in the promoter region, IVSI-23 C>T and IVS3-48 T>C of FECH gene were also studied in all the patients and their available relatives.
Patients
Five unrelated Argentinean EPP families were studied. Informed consent was obtained from all patients prior to their inclusion in the study.
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Family 1: The proband is a 48 years old woman diagnosed at the age of 35 who has had cutaneous photosensitivity since she was 6 months old. No other family member has any clinical symptom of EPP. Samples from her sister (59 years old) and her brother (57 years old) were also available.
Family 2: The proband is a 43 years old man diagnosed at the age of 26. He had mild photosensitivity starting at the age of 4. His father's brother was also diagnosed as EPP at the age of 34. Samples from his two daughters (15 and 10 years old) were also available for investigation.
Patient 3: The proband is a 35 years old man diagnosed at the age of 29 who has had cutaneous manifestations since he was 5 years old. One nephew shows similar cutaneous symptoms. There were no relatives available for testing.
Patient 4: The proband is a 26 years old man diagnosed at the age of 15. Cutaneous photosensitivity began at the age of 9 after having received antihistaminics for an infectious syndrome. His parents and his 3 sisters show no clinical symptoms and they are also biochemically normal, but no samples were available for genetic studies. 
of FECH activity about 25% of the control. It is of note that the value of 6.0 given for the mother in family 5 is not significant even it is out of normal values (Table 1) .
In family 1, sequencing of amplified genomic DNA with both, sense and anti-sense primers, showed a novel point mutation in the acceptor site of splicing in intron 1 (IVS1-2 A>G) . To analyze the effect of this mutation in the mRNA processing, amplification and sequencing of cDNA was performed, showing skipping of exon 2 in this patient (Fig 2A) . Both her sister and brother did not have the mutation. The proband inherited haplotype -251G/G; IVS1-23 T/T; IVS3-48 T/C for the polymorphisms studied (Table 3) .
In family 2, we have found a known frameshift mutation in exon 4, 400delA that produces a stop codon at codon position 144 as described by Wang et al in 1997 (22) . His two daughters are carriers for this mutation. The patient presented the -251A/G; IVS1-23 C/T; IVS3-48 T/C haplotype and one of his daughters inherited the normal C/C allele for the IVS1-23 polymorphism but unfortunately the IVS3-48 T/C polymorphism could not be analyzed for either of his daughters (Table 3) .
In patient 3, a novel small deletion in exon 4 was detected, 451delT, which produces a frameshift and a stop codon at codon position 169 (Fig 2B) The patient also presented the -251 A/G; IVS1-23 C/T; IVS3-48 T/C polymorphisms (Table 3) . No relative was available for the study.
In patient 4, another novel point mutation in the acceptor site of splicing of intron 4 was detected, IVS4-2 A>G Sequencing of the cDNA resulted in the loss of the first 48 bp of exon 5 but not the skipping of the entire exon, which is probably due to the use of the first AG downstream of the mutation site as a cryptic splicing site (Fig.2C) . The proband has the haplotype: -251A/G; IVS1-23 C/T, IVS3-48 T/C (Table 3) . No relative was available to be included in the study.
In family 5, both brothers showed a known nonsense mutation in exon 4, 343C/T, yielding a stop codon at the arginine 115 (R115X) as described by Henriksson This is the first study performed in five unrelated Argentinean EPP families at the molecular level.
We have found 3 novel mutations and 2 previously described (22, 23) . The 3 new mutations were null mutations: 2 splicing mutations and one small deletion.
In the proband of family 1 a splicing mutation due to the transition a → g in intron 1 leading to exon 2 skipping (IVS1-2 A>G) was detected as it is shown by DNA and cDNA sequencing results
(Figure 1)
In patient 4 we have detected another new splicing mutation in intron 4 (IVS4-2 A>G) (Figure 3 ). This mutation alters the acceptor splice site of intron 4 producing the loss of the first 48 bp of exon 5 due to the use of the first cryptic site (AG) located downstream the mutation (Figure 3 ). This is actually the first report about the use of a cryptic site among all the mutations described for the FECH gene.
A new deletion (451delT) that produces a stop codon 18 codons downstream the deletion was found in patient 3 ( Figure 2 ).
In the other two families 2 previously described mutations producing stop codons: 400delA (22) and 343C>T (23) were detected.
All the 6 symptomatic patients had a FECH activity 25% of normal value (Table 1) 
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of a low expressed allele together with the mutation in the FECH gene are necessary for the clinical expression of this porphyria (4, 13, 14, 16, (25) (26) (27) .
In family 2, both daughters (at present 17 and 12 years old) are carriers of the FECH mutation. As the oldest one is still asymptomatic and bears the normal allele for IVS1-23 polymorphism, we can assume that she will have the normal haplotype for the other two polymorphisms as well as it is likely that her sister also has the normal haplotype for the IVS3-48C low expression allele. It is highly possible that both will remain asymptomatic.
In family 5, the proband and his brother carried both the 343C>T mutation and the low-expression allele and are symptomatic. Their sister, who carried the mutation and had the normal haplotype and a FECH enzyme activity 50% of normal value was asymptomatic and according to Gouya et al (10) she has a risk of less than 2% to became symptomatic. Moreover, as the patient and his brother have inherited the low-expression haplotype from their mother we can assume that the asymptomatic father in this family must have the haplotype -251 A/A, IVS1-23 C/C, IVS3 -48 T/T and thus did not manifest the disease. This mutation, first described in a Finnish patient (22) , has been also found in patients from France (28), Spain (26, 29) Italy (30), Sweden (13) and China (31) . Of the seven patients who carried 343C>T mutation, only three suffered from liver disease (13, 28, 31) . The reason for this
is not yet well understood.
Although it has been observed that "null allele" mutations inducing the production of a truncated protein are generally associated with liver complications, our patients, all carrying "null allele" mutations in the FECH gene have not up to the time of the study shown any sign of liver disease. We do however recommend that their liver function be periodically controlled to detect any complications.
We conclude that early knowledge of the mutation and associated polymorphisms in a biochemically-diagnosed individual is important to make a proper diagnosis and to initiate symptomatic treatment as well as surveillance and timely interventions to avoid severe protoporphyrin related liver disease. Molecular Medicine
